子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于增强病毒效力的组合物和方法 | CN201080036267.6 | 2010-07-07 | CN102471300B | 2016-04-13 | 约翰·贝尔; 让-西蒙·迪亚洛; 法布里斯·勒伯夫 |
| 提供了病毒敏化化合物，所述化合物通过增加病毒在细胞中的扩散、增加细胞中病毒的滴度或增加病毒对细胞的细胞毒性来增强病毒的效力。还提供了使用所述化合物的其他用途、组合物和方法。 | ||||||
| 2 | 镀液及镀覆方法 | CN201110121339.3 | 2011-03-15 | CN102276796B | 2013-04-24 | Z·I·尼亚齐比托瓦 |
| 提供在导体层的表面上沉积铜的铜电镀液，其含有整平剂，该整平剂是某些咪唑与某些环氧化合物的反应产物。还公开了使用这种铜电镀液沉积铜的方法。提供了一种或多种含氮化合物与一种或多种如结构式(I)或(II)所示的含环氧的化合物的反应产物，其中Y1和Y2分别选自H和(C1-C4)烷基；Z是Ar、R12OArOR12、(R13O)aAr(OR13)a、Cy、R12CyR12或者(R13O)aCy(OR13)a；r＝1-4；Ar＝(C6-C18)芳基；Cy＝(C5-C12)环烷基；每个R12表示(C1-C8)烷基；每个R13表示(C2-C6)亚烷基氧基；每个a＝1-10；并且A表示C5-C12环烷基。 | ||||||
| 3 | S1P受体调节剂以及它们的用途 | CN200980141188.9 | 2009-10-19 | CN102186845A | 2011-09-14 | 古尔米特·S·基尔; 达米安·W·格罗贝尔尼 |
| 本发明涉及具有S1P受体调节活性的新颖的化合物。此外，本发明涉及一种包括至少一种本发明的化合物的药物，该药物用于治疗由不适当的S1P受体调节活性或表达例如自身免疫应答所引起的或与之相关的疾病和/或病症。本发明的另一个方面涉及包括至少一种本发明的化合物的一种药物的用途，该药物用于制造一种药剂，该药剂用于治疗由不适当的S1P受体调节活性或表达例如自身免疫应答所引起的或与之相关的疾病和/或病症。 | ||||||
| 4 | 高传导率钙-活化K通道开启剂 | CN02808370.9 | 2002-04-15 | CN100540538C | 2009-09-16 | 本宫光弥; 保坂俊弘; 柏木俊彦; 河野理夏子; 小林弘幸 |
| 一种高传导率钙-活化K通道开启剂，其包括一种作为活性成分的由下式(I)表示的含氮5元杂环化合物：其中X表示N-R4，O或S，R1与R2各自独立地表示氢，卤素，羧基，氨基，低级烷基，低级烷氧羰基，低级链烯基，环-低级烷基，氨基甲酰基，芳基，杂环基或杂环基-取代的羰基，R3表示芳基，杂环基或低级烷基，和R4表示氢原子或低级烷基。 | ||||||
| 5 | 用于金和金合金的表面处理溶液 | CN201610444326.2 | 2016-06-20 | CN106319587A | 2017-01-11 | 美津浓洋子; 近藤真琴; K·蓬田; T·森永 |
| 本发明涉及一种组合物，其含有从含氮杂环化合物与表卤代醇的反应产物获得的阳离子聚合物；和磷化合物。所述组合物可用作金或金合金的表面处理剂。所述组合物可密封金或金合金的表面上的小孔。 | ||||||
| 6 | S1P受体调节剂以及它们的用途 | CN200980141188.9 | 2009-10-19 | CN102186845B | 2016-09-07 | 古尔米特·S·基尔; 达米安·W·格罗贝尔尼 |
| 本发明涉及具有S1P受体调节活性的新颖的化合物。此外，本发明涉及一种包括至少一种本发明的化合物的药物，该药物用于治疗由不适当的S1P受体调节活性或表达例如自身免疫应答所引起的或与之相关的疾病和/或病症。本发明的另一个方面涉及包括至少一种本发明的化合物的一种药物的用途，该药物用于制造一种药剂，该药剂用于治疗由不适当的S1P受体调节活性或表达例如自身免疫应答所引起的或与之相关的疾病和/或病症。 | ||||||
| 7 | 用于增强病毒效力的组合物和方法 | CN201080036267.6 | 2010-07-07 | CN102471300A | 2012-05-23 | 约翰·贝尔; 让-西蒙·迪亚洛 |
| 提供了病毒敏化化合物，所述化合物通过增加病毒在细胞中的扩散、增加细胞中病毒的滴度或增加病毒对细胞的细胞毒性来增强病毒的效力。还提供了使用所述化合物的其他用途、组合物和方法。 | ||||||
| 8 | 高传导率钙-活化K通道开启剂 | CN200910004656.X | 2002-04-15 | CN101519386A | 2009-09-02 | 本宫光弥; 保坂俊弘; 柏木俊彦; 河野理夏子; 小林弘幸 |
| 一种高传导率钙－活化K通道开启剂，其包括一种作为活性成分的由下式(I)表示的含氮5元杂环化合物：其中X表示N－R4，O或S，R1与R2各自独立地表示氢，卤素，氨基，低级烷基，低级烷氧羰基，低级链烯基，环低级烷基，氨基甲酰基，芳基，杂环基或杂环基－取代的羰基，R3表示芳基，杂环基或低级烷基，和R4表示氢原子或低级烷基。 | ||||||
| 9 | 镀液及镀覆方法 | CN201110121339.3 | 2011-03-15 | CN102276796A | 2011-12-14 | Z·I·尼亚齐比托瓦 |
| 提供在导体层的表面上沉积铜的铜电镀液，其含有整平剂，该整平剂是某些咪唑与某些环氧化合物的反应产物。还公开了使用这种铜电镀液沉积铜的方法。提供了一种或多种含氮化合物与一种或多种如结构式(I)或(II)所示的含环氧的化合物的反应产物，其中Y1和Y2分别选自H和(C1-C4)烷基；Z是Ar、R12OArOR12、(R13O)aAr(OR13)a、Cy、R12CyR12或者(R13O)aCy(OR13)a；r＝1-4；Ar＝(C6-C18)芳基；Cy＝(C5-C12)环烷基；每个R12表示(C1-C8)烷基；每个R13表示(C2-C6)亚烷基氧基；每个a＝1-10；并且A表示C5-C12环烷基。 | ||||||
| 10 | 用于染料敏化太阳能电池的染料和染料敏化太阳能电池 | CN200980114026.6 | 2009-03-19 | CN102027631A | 2011-04-20 | 濑川浩司; 久保贵哉; 中崎城太郎; 大谷直树 |
| 本发明公开了用于染料敏化太阳能电池的染料，其对多孔金属氧化物表现出高的亲和性和附着性，同时在有机溶剂中具有优异的溶解性。该用于染料敏化太阳能电池的染料含有式(1)表示的特定磷酰基噻吩化合物。还公开了使用用于该染料敏化太阳能电池的染料的染料敏化太阳能电池。 | ||||||
| 11 | 过渡金属配位化合物和使用该过渡金属配位化合物的共轭芳香族化合物的制造方法 | CN200880112588.2 | 2008-07-25 | CN101827854A | 2010-09-08 | 浅海拓; 神川卓 |
| 本发明提供使式(1)所表示的联吡啶化合物(R1、R2和R3表示可以被取代的碳原子数1～10的烷基等，R4和R5表示氢原子等)与第9族、第10族或第11族过渡金属化合物接触而得到的过渡金属配位化合物，以及共轭芳香族化合物的制造方法，其特征在于，在上述过渡金属配位化合物的存在下，使芳香环上结合有1个或2个离去基团的芳香族化合物(A)和与其具有相同结构的芳香族化合物(A)发生反应、或者和与所述芳香族化合物(A)在结构上不同的芳香族化合物(B)发生反应，所述芳香族化合物(B)在芳香环上结合有1个或2个离去基团。 | ||||||
| 12 | 超扭转向列液晶显示器、液晶组合物和化合物 | CN00819217.0 | 2000-12-14 | CN1248033C | 2006-03-29 | D·伊昂尼斯库; M·佛朗西斯; D·考特斯 |
| 本发明涉及具有短开关时间及良好的陡度和角度依赖性的超扭转向列液晶显示器(STN-LCD)，和其中使用的新型向列型液晶混合物，其包括通式(A)的化合物与通式(IB)的化合物，其中R3、R4、L1、L2、m、Y1、Y2和W具有文中给出的含义，还涉及通式(IA)的化合物。 | ||||||
| 13 | 高传导率钙－活化K通道开启剂 | CN02808370.9 | 2002-04-15 | CN1503786A | 2004-06-09 | 本宫光弥; 保坂俊弘; 柏木俊彦; 河野理夏子; 小林弘幸 |
| 一种高传导率钙－活化K通道开启剂，其包括一种作为活性成分的由下式(I)表示的含氮5元杂环化合物：其中X表示N－R4，O或S，R1与R2各自独立地表示氢，卤素，羧基，氨基，低级烷基，低级烷氧羰基，低级链烯基，环－低级烷基，氨基甲酰基，芳基，杂环基或杂环基－取代的羰基，R3表示芳基，杂环基或低级烷基，和R4表示氢原子或低级烷基。 | ||||||
| 14 | 超扭转向列液晶显示器、液晶组合物和化合物 | CN00819217.0 | 2000-12-14 | CN1437647A | 2003-08-20 | D·伊昂尼斯库; M·佛朗西斯; D·考特斯 |
| 本发明涉及具有短开关时间及良好的陡度和角度依赖性的超扭转向列液晶显示器(STN－LCD)，和其中使用的新型向列型液晶混合物，其包括通式(A)的化合物与通式(IB)的化合物，其中R3、R4、L1、L2、m、Y1、Y2和W具有文中给出的含义，还涉及通式(IA)的化合物。 | ||||||
| 15 | S1P receptors modulators and their use thereof | US14920780 | 2015-10-22 | US09707205B2 | 2017-07-18 | Gurmit S. Gill; Damian W. Grobelny |
| The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response. | ||||||
| 16 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | US14920780 | 2015-10-22 | US20160038455A1 | 2016-02-11 | GURMIT S. GILL; DAMIAN W. GROBELNY |
| The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response. | ||||||
| 17 | S1P Receptors Modulators and Their Use Thereof | US14066276 | 2013-10-29 | US20140066427A1 | 2014-03-06 | Gurmit S. Gill; Damian W. Grobelny |
| The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response. | ||||||
| 18 | Thiazole and thiophene compounds | US13399106 | 2012-02-17 | US08404859B2 | 2013-03-26 | Paul Gillespie; Christophe Michoud; Kenneth Carey Rupert; Kshitij Chhabilbhai Thakkar |
| Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD. | ||||||
| 19 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | US12673846 | 2008-07-25 | US08088883B2 | 2012-01-03 | Taku Asaumi; Takashi Kamikawa |
| A transition metal complex obtained by contacting a bipyridine compound represented by the formula (1): wherein R1, R2 and R3 represent a C1-C10 alkyl group which may be substituted, etc., and R4 and R5 represent a hydrogen atom etc., with a compound of a transition metal belonging to Group 9, 10 or 11, and a process for producing a conjugated aromatic compound comprising reacting an aromatic compound (A) wherein one or two leaving groups are bonded to an aromatic ring with an aromatic compound (A) having the same structure as that of the above-mentioned aromatic compound (A) or an aromatic compound (B) being structurally different from the above-mentioned aromatic compound (A) and having one or two leaving groups bonded to an aromatic ring, in the presence of said transition metal complex. | ||||||
| 20 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | US12673846 | 2008-07-25 | US20110046336A1 | 2011-02-24 | Taku Asaumi; Takashi Kamikawa |
| A transition metal complex obtained by contacting a bipyridine compound represented by the formula (1): wherein R1, R2 and R3 represent a C1-C10 alkyl group which may be substituted, etc., and R4 and R5 represent a hydrogen atom etc., with a compound of a transition metal belonging to Group 9, 10 or 11, and a process for producing a conjugated aromatic compound comprising reacting an aromatic compound (A) wherein one or two leaving groups are bonded to an aromatic ring with an aromatic compound (A) having the same structure as that of the above-mentioned aromatic compound (A) or an aromatic compound (B) being structurally different from the above-mentioned aromatic compound (A) and having one or two leaving groups bonded to an aromatic ring, in the presence of said transition metal complex. | ||||||
QQ群二维码
意见反馈
意见反馈